TNF Pharmaceuticals Inc
Company Profile
Business description
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.
Contact
855 North Wolfe Street
Suite 601
BaltimoreMD21205
USAT: +1 856 848-8698
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,149.90 | 8.80 | -0.11% |
| CAC 40 | 8,042.95 | 51.25 | -0.63% |
| DAX 40 | 22,891.68 | 107.47 | -0.47% |
| Dow JONES (US) | 41,985.35 | 32.03 | 0.08% |
| FTSE 100 | 8,646.79 | 55.20 | -0.63% |
| HKSE | 23,658.45 | 31.27 | -0.13% |
| NASDAQ | 17,784.05 | 92.42 | 0.52% |
| Nikkei 225 | 37,718.50 | 41.44 | 0.11% |
| NZX 50 Index | 12,102.92 | 10.62 | -0.09% |
| S&P 500 | 5,667.56 | 4.67 | 0.08% |
| S&P/ASX 200 | 7,927.20 | 4.00 | -0.05% |
| SSE Composite Index | 3,369.70 | 4.87 | 0.14% |